Hoth Therapeutics Partners to Accelerate HT-ALZ Development with LTS Therapy Systems

July 24, 2024

DENVER, Colo., Jul 24, 2024 (247marketnews.com)- Hoth Therapeutics, Inc. (NASDAQ:HOTH) and LTS Therapy Systems, LLC agreed to work together on the development and manufacturing of HT-ALZ oral film prototype, which is being developed as a novel therapeutic solution for Alzheimer’s Disease based on its preclinical results released earlier this year. HT-ALZ’s pre-clinical results indicate that it’s able to restore cognitive functions and improve quality of life for subjects suffering from Alzheimer’s disease.

Robb Knie, Hoth’s CEO, commented, “Hoth is excited to announce this partnership and the next milestone in our development of HT-ALZ.

“We are leveraging LTS’s expertise to develop and manufacture the oral film prototypes needed for this particular population and leveraging our positive preclinical results to advance our Alzheimer’s therapeutic.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (HOTH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.